Randomized Trials
RCT | High-dose hemodiafiltration reduces mortality risk in kidney failure patients compared to conventional high-flux hemodialysis
19 Jun, 2023 | 14:17h | UTCEffect of Hemodiafiltration or Hemodialysis on Mortality in Kidney Failure – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
#ERA23: In patients with kidney failure undergoing kidney-replacement therapy, the use of high-dose hemodiafiltration resulted in lower mortality than conventional high-flux hemodialysis. Full results of the CONVINCE trial: https://t.co/NRtQnHm9vo
— NEJM (@NEJM) June 16, 2023
RCT | Video laryngoscopy improves first-attempt intubation, severe complications unchanged
19 Jun, 2023 | 14:15h | UTCVideo versus Direct Laryngoscopy for Tracheal Intubation of Critically Ill Adults – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Study shows video laryngoscope increases successful intubation on first attempt – Vanderbilt University Medical Center
RCT | Fruquintinib extends median survival to 7.4 months vs. 4.8 months with placebo in refractory metastatic colorectal cancer
19 Jun, 2023 | 14:02h | UTCFruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter questioning the control group (thread – click for more)
Disgusting, unethical PLACEBO control trial in colon cancer just so Fruquitinib can win
I will show you that placebo should not have been the control arm, & the IRBs & FDA failed ?
First, this trial tests a new drug vs. placebo (sugar pill) in patients dying of colon cancer pic.twitter.com/fa915vgUbp
— Vinay Prasad MD MPH (@VPrasadMDMPH) June 17, 2023
RCT | Adding bio-impedance to fluid management fails to enhance kidney function preservation in new hemodialysis patients
19 Jun, 2023 | 14:01h | UTC
RCT | Mild hypercapnia after cardiac arrest shows no improvement in neurological outcomes vs. normocapnia
16 Jun, 2023 | 14:15h | UTCMild Hypercapnia or Normocapnia after Out-of-Hospital Cardiac Arrest – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: New data supports current management of CO2 levels in cardiac arrest patients – UCD Dublin
RCT | Cisplatin–gemcitabine improves 3-year progression-free survival in N2–3 nasopharyngeal carcinoma compared to cisplatin–fluorouracil
16 Jun, 2023 | 14:05h | UTCConcurrent chemoradiotherapy followed by adjuvant cisplatin–gemcitabine versus cisplatin–fluorouracil chemotherapy for N2–3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
NOW OF: Concurrent chemoradiotherapy followed by adjuvant cisplatin–gemcitabine versus cisplatin–fluorouracil chemotherapy for N2–3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trialhttps://t.co/n6WalQiRfo pic.twitter.com/vE4VASUIgM
— The Lancet Oncology (@TheLancetOncol) June 5, 2023
RCT | Increased detection of metastases via PET-CT alters treatment path in locally advanced breast cancer
16 Jun, 2023 | 14:02h | UTCImpact of 18F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer – Journal of Clinical Oncology (link to abstract – $ for full-text)
RCT | Prehospital use of tranexamic acid in severe trauma cases shows no superiority over placebo
15 Jun, 2023 | 15:16h | UTCPrehospital Tranexamic Acid for Severe Trauma – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Shining a new light on tranexamic acid for trauma care – Monash University
Commentary on Twitter
Late breaking at #CCR23: In the PATCH-Trauma trial involving adults with major trauma, treatment with tranexamic acid did not result in a greater number of patients surviving with a favorable functional outcome at 6 months than placebo. https://t.co/i8fu34ReCB pic.twitter.com/GEOtRphOBb
— NEJM (@NEJM) June 14, 2023
RCT | No significant kidney outcome differences observed across glucose-lowering medications in T2D patients
15 Jun, 2023 | 15:02h | UTCComparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial – JAMA Internal Medicine (link to abstract – $ for full-text)
See also: Visual Abstract
Commentaries:
No differences found in effects of secondary diabetes drugs on kidney outcomes – ACP Diabetes
Do glucose-lowering medications have different effects on kidney outcomes? – News Medical
RCT | Sublingual microcirculatory assessment fails to reduce 30-day mortality in shock patients
15 Jun, 2023 | 15:00h | UTC
Commentary on Twitter
Direct assessment of microcirculation in shock, prospective multicenter RCT
?knowledge of sublingual microcirculatory perfusion variables resulted in significantly more therapy adjustments
?these changes did not improve 30d survival
#FOAMcc @yourICM
?️ https://t.co/Mn5bAqjDtS pic.twitter.com/i3zPwomb0V— Intensive Care Medicine (@yourICM) June 6, 2023
RCT | Nalbuphine reduces cough in idiopathic pulmonary fibrosis, despite adverse effects
15 Jun, 2023 | 14:55h | UTCNalbuphine Tablets for Cough in Patients with Idiopathic Pulmonary Fibrosis – NEJM Evidence
RCT | 0.01% atropine effective in reducing progression of myopia in children over 3 years
14 Jun, 2023 | 14:41h | UTCNews Release: Eye drops slow nearsightedness progression in kids – Ohio State University
See also: Visual Abstract
Related:
RCT | Effect of low-concentration atropine eyedrops vs. placebo on myopia incidence in children
Crossover RCT | Spectacle lenses with highly aspherical lenslets for slowing myopia.
RCT | Effect of text messaging parents of school-aged children on outdoor time to control myopia.
RCT | Myopia control effect of repeated low-level red-light therapy in children.
RCT | Talazoparib plus enzalutamide prolongs radiographic PFS vs. enzalutamide alone in metastatic castration-resistant prostate cancer
14 Jun, 2023 | 14:29h | UTCTalazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)
RCT | Second-line treatment with Axi-cel results in increased overall survival in large B-cell lymphoma
14 Jun, 2023 | 14:25h | UTCSurvival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Late breaking at #ASCO23: In the phase 3 ZUMA-7 trial, patients with relapsed or refractory large B-cell lymphoma who received axi-cel (CD19-specific CAR T cells) had a 27.4% lower risk of death than patients who received standard therapy. Full trial results:
— NEJM (@NEJM) June 5, 2023
Crossover RCT | THC and Cannabidiol demonstrate potential in Tourette syndrome tic management, despite cognitive impacts
14 Jun, 2023 | 14:27h | UTCTetrahydrocannabinol and Cannabidiol in Tourette Syndrome – NEJM Evidence
RCT | Cilta-cel shows superior progression-free survival over standard care in lenalidomide-refractory multiple myeloma
14 Jun, 2023 | 14:22h | UTCCilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Original Article: Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4) https://t.co/Wag2UTKOfH#ASCO23
— NEJM (@NEJM) June 6, 2023
RCT | Valbenazine outperforms placebo in alleviating chorea in Huntington’s disease
14 Jun, 2023 | 14:18h | UTCSafety and efficacy of valbenazine for the treatment of chorea associated with Huntington’s disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial – The Lancet Neurology (link to abstract – $ for full-text)
RCT | No change in delayed graft function with normothermic perfusion vs. cold storage in kidney transplants
13 Jun, 2023 | 14:00h | UTC
Commentary on Twitter
In an open-label, randomized controlled trial, normothermic machine perfusion of kidneys from donation after circulatory death was found to be feasible and safe but did not reduce the rate of delayed graft function compared to static cold storage. https://t.co/faaAzK3bpc pic.twitter.com/iL7Je7Z7jO
— Nature Medicine (@NatureMedicine) June 2, 2023
RCT | Capivasertib–fulvestrant improves PFS vs. fulvestrant alone in HR+ advanced breast cancer
13 Jun, 2023 | 13:54h | UTCCapivasertib in Hormone Receptor–Positive Advanced Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Video: Capivasertib in Advanced Breast Cancer | NEJM
Commentary: Capivasertib-fulvestrant therapy increases PFS in HR-positive breast cancer – MedicalXpress
Commentary on Twitter
Among persons with breast cancer previously treated with hormonal therapy, the AKT pathway inhibitor capivasertib when added to fulvestrant significantly prolonged progression-free survival as compared with fulvestrant alone. Full results of CAPItello-291: https://t.co/ZCBHkG305b
— NEJM (@NEJM) May 31, 2023
RCT | Multivitamin supplementation may improve memory in aged adults
7 Jun, 2023 | 14:12h | UTCMultivitamin Supplementation Improves Memory in Older Adults: A Randomized Clinical Trial – The American Journal of Clinical Nutrition (link to abstract – $ for full-text)
News Releases:
Multivitamin Improves Memory in Older Adults, Study Finds – Columbia University
Related Research: Effects of cocoa extract and a multivitamin on cognitive function: A randomized clinical trial – Alzheimer’s & Dementia
RCT | Preoperative FOLFOX noninferior to chemoradiotherapy in locally advanced rectal cancer
7 Jun, 2023 | 14:06h | UTCPreoperative Treatment of Locally Advanced Rectal Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Related Publication: Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048) – Journal of Clinical Oncology
Commentary: Radiation May Be Safely Omitted in Select Patients With Locally Advanced Rectal Cancer – The ASCO Post
Commentary on Twitter
Original Article: Preoperative Treatment of Locally Advanced Rectal Cancer (PROSPECT) https://t.co/6ubagrEzyw#ASCO23 pic.twitter.com/g2XFBkEk4T
— NEJM (@NEJM) June 5, 2023
RCT | Vorasidenib enhances PFS in IDH1/2-mutant low-grade glioma, trial methods debated online
7 Jun, 2023 | 14:04h | UTCVorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Vorasidenib Delays Disease Progression or Death in Patients With Grade 2 IDH-Mutated Glioma – The ASCO Post
Commentary on Twitter questioning study methodology (thread – click for more)
This is a rather troubling study. The fact that it got published in @NEJM is concerning, to say the least
Astonishing cost of $16 000/month for a drug administered continuously until disease progression in a trial with a dubious endpoint and flawed design
Here are my thoughts: https://t.co/E3QtZfEyQw
— Stanislav (Stas) Lazarev, MD (@StasLazarev) June 5, 2023
RCT | Atezolizumab and cabozantinib combo fails to outperform cabozantinib alone in renal cell carcinoma
7 Jun, 2023 | 13:54h | UTCAtezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial – The Lancet (free registration required)
Commentary from the author on Twitter (thread – click for more)
1/ Results from #CONTACT03 are out both @ASCO #ASCO23 and @TheLancet . The 1⃣st phase 3 trial to assess the efficacy of rechallenge with anti-PDL1 in ANY cancer type.
Kudos to @montypal, SC members, @roche, our patients, = for this phenomenal job. https://t.co/p7hYD4snXA pic.twitter.com/CXk1vqfB26— Toni Choueiri, MD (@DrChoueiri) June 5, 2023
RCT | Adding dalpiciclib to standard letrozole or anastrozole treatment outperforms placebo in HR+, HER2- advanced breast cancer
7 Jun, 2023 | 13:44h | UTCDalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: Dalpiciclib Combo Improves PFS Vs Placebo in HER2– Advanced Breast Cancer – Cancer Network
RCT | Immediate vs. delayed sequential bilateral cataract surgery: non-inferior in safety, higher cost-effectiveness
6 Jun, 2023 | 14:41h | UTCSafety, effectiveness, and cost-effectiveness of immediate versus delayed sequential bilateral cataract surgery in the Netherlands (BICAT-NL study): a multicentre, non-inferiority, randomised controlled trial – The Lancet (link to abstract – $ for full-text)
News Release: Cataract surgery: two-sided treatment better than one-by-one approach – Maastricht University